Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAP-219 in Adult Participants With Focal Seizures
NCT07563881Phase 3Recruiting
- Sponsor
- Rapport Therapeutics
- Start
- Jun 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of RAP-219 in focal epilepsy (3 arms), sponsored by Rapport Therapeutics. Primary endpoint: Median Percent Change in Seizure Frequency at 14 weeks. Started Jun 2026; status: recruiting.
02
Drugs
RAP-219
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT07563881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563881.